Literature DB >> 9756870

Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.

Y Huang1, X Q Liu, S C Rall, J M Taylor, A von Eckardstein, G Assmann, R W Mahley.   

Abstract

The molecular mechanisms of hypertriglyceridemia (HTG), a common lipid metabolic disorder in humans, often of genetic origin, are not well understood. In studying the effect of apolipoprotein (apo) E on the metabolism of triglyceride-rich lipoproteins, we found that expressing high plasma levels of human apoE3 in transgenic mice lacking endogenous mouse apoE caused HTG. These transgenic animals had 3-fold higher plasma triglyceride levels, higher very low density lipoproteins (VLDL), and lower high density lipoproteins than did nontransgenics. Removing one or both low density lipoprotein receptor alleles in the apoE3-overexpressing mice caused severe HTG (8-11-fold over nontransgenics) and increased VLDL and decreased low and high density lipoproteins, and apoE3-enriched VLDL were markedly depleted in apoC-II. At least two mechanisms could explain HTG associated with apoE3 overexpression: stimulated VLDL triglyceride production and impaired VLDL lipolysis. The apoE3 mice with HTG had a 50% increase in hepatic VLDL triglyceride production. Furthermore, overexpression of apoE (E2, E3, or E4) in cultured hepatocytes (McA-RH7777 cells) correlated positively with secretion of VLDL into the medium. However, apoE3 overexpression-associated HTG was only partially explained by VLDL overproduction, as lipoprotein lipase-mediated VLDL lipolysis was also decreased 20-86% depending on apoE3 levels, most likely by displacing or masking apoC-II on the particles. In human subjects, HTG correlated positively with increased VLDL triglyceride and plasma and VLDL apoE levels. However, plasma and VLDL apoE correlated negatively with VLDL apoC-II levels and lipoprotein lipase-mediated VLDL lipolysis. Thus, optimal expression of apoE is crucial for normal metabolism of triglyceride-rich lipoproteins, and overexpression and/or accumulation of apoE may contribute to HTG by stimulating VLDL triglyceride production and by impairing VLDL lipolysis. The apoE3-overexpressing mice will be useful for studying the pathophysiology of this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756870     DOI: 10.1074/jbc.273.41.26388

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  Biochemistry       Date:  2011-02-20       Impact factor: 3.162

2.  Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease.

Authors:  Yuji Kajiwara; Sonia Franciosi; Nagahide Takahashi; Lisa Krug; James Schmeidler; Kevin Taddei; Vahram Haroutunian; Ulrik Fried; Michelle Ehrlich; Ralph N Martins; Samuel Gandy; Joseph D Buxbaum
Journal:  Mol Neurodegener       Date:  2010-01-14       Impact factor: 14.195

3.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

4.  The role of the LDL receptor in apolipoprotein B secretion.

Authors:  J Twisk; D L Gillian-Daniel; A Tebon; L Wang; P H Barrett; A D Attie
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

6.  Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors:  Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

7.  Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.

Authors:  Paolo Parini; Ulf Gustafsson; Matt A Davis; Lilian Larsson; Curt Einarsson; Martha Wilson; Mats Rudling; Hiroshi Tomoda; Satoshi Omura; Staffan Sahlin; Bo Angelin; Lawrence L Rudel; Mats Eriksson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

8.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

9.  A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice.

Authors:  Konstantinos Drosatos; Despina Sanoudou; Kyriakos E Kypreos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2007-04-24       Impact factor: 5.157

10.  The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.

Authors:  Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.